FDA authorizes Novavax as new alternative to mRNA COVID-19 vaccines
CBSN
The Food and Drug Administration has granted Novavax's COVID-19 vaccine emergency use authorization, paving the way for a new fourth option for the 10% of American adults who have yet to receive at least one dose of any other shot.
"Today's authorization offers adults in the United States who have not yet received a COVID-19 vaccine another option that meets the FDA's rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization," said FDA Commissioner Dr. Robert Califf in a release on Wednesday.
Like the other available COVID-19 vaccines, Novavax's shots will need to be formally recommended by the Centers for Disease Control and Prevention before they can be made available. That could happen as soon as next Tuesday, when the agency's outside vaccine advisers are next scheduled to meet.
